Načítá se...
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer
BACKGROUND. The TMPRSS2/ERG (TE) fusion gene is present in half of prostate cancers. The TMPRSS2 and ERG junction of the fusion mRNA constitutes a cancer specific target. Although docetaxel-based chemotherapy is the second line of therapy following development resistance to androgen ablation therapi...
Uloženo v:
| Vydáno v: | Prostate |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6925833/ https://ncbi.nlm.nih.gov/pubmed/31614005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23918 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|